Medicare AdvantageCoverageLow impact
MA08.086d, Nusinersen (Spinraza®)
Independence Blue Cross·Neurology, Pediatrics·Pharmacy
Effective date
Oct 2, 2024
We identified it
Jun 19, 2026
Summary
The Nusinersen (Spinraza®) policy MA08.086d has been reissued effective October 2, 2024 for Medicare Advantage plans. This represents an updated version of an existing pharmacy policy for this spinal muscular atrophy medication.
Action Required
Review the updated Nusinersen (Spinraza®) policy MA08.086d at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing guidelines for this specialty medication used to treat spinal muscular atrophy.